



## PREFERRED SPECIALTY MANAGEMENT POLICY

- POLICY:** Oncology – Everolimus Products Preferred Specialty Management Policy
- Afinitor® (everolimus tablets – Novartis, generic)
  - Afinitor Disperz® (everolimus tablets for oral suspension Novartis, generic)
  - Torpenz™ (everolimus tablets – Upsher-Smith)

**REVIEW DATE:** 06/26/2024; selected revision 09/25/2024

### **INSTRUCTIONS FOR USE**

THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS, DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.

## **CIGNA NATIONAL FORMULARY COVERAGE:**

### **OVERVIEW**

Everolimus, a kinase inhibitor, is indicated for the following conditions:<sup>1,2</sup>

- **Breast cancer**, treatment of postmenopausal women with advanced hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease in combination with exemestane, after failure of treatment with letrozole or anastrozole.
- **Neuroendocrine tumors**, treatment of progressive disease of pancreatic origin and progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are unresectable, locally advanced, or metastatic in adults. Limitation of Use: Afinitor is not indicated for the treatment of patients with functional carcinoid tumors.
- **Renal cell carcinoma**, treatment of advanced disease after failure of treatment with sunitinib or sorafenib in adults.
- **Tuberous sclerosis complex (TSC)-associated renal angiomyolipoma**, not requiring immediate surgery in adults.

- **TSC-associated subependymal giant cell astrocytoma (SEGA)**, that requires therapeutic intervention but cannot be curatively resected in patients ≥ 1 year of age. Afinitor Disperz is also FDA-approved for this indication.
- **TSC-associated partial-onset seizures**, adjunctive treatment of patients ≥ 2 years of age. Only Afinitor Disperz is FDA-approved for this indication.

**POLICY STATEMENT**

This Preferred Specialty Management program has been developed to encourage the use of Preferred Products. For all medications (Preferred and Non-Preferred), the patient is required to meet the respective standard *Oncology – Everolimus Products Prior Authorization Policy* criteria. The program also directs the patient to try one Preferred Product prior to the approval of a Non-Preferred Product. Requests for Non-Preferred Products will also be reviewed using the exception criteria (below). If the patient meets the standard *Oncology – Everolimus Products Prior Authorization Policy* criteria but has not tried a Preferred Product, approval for a Preferred Product will be authorized. All approvals are provided for 1 year in duration.

**Afinitor (Brand) Preferred Specialty Management Program**

**Preferred Product:** generic everolimus tablets, Torpenz

**Non-Preferred Product:** Afinitor tablets (brand)

**Afinitor Disperz (Brand) Preferred Specialty Management Program**

**Preferred Product:** generic everolimus tablets for oral suspension

**Non-Preferred Product:** Afinitor Disperz tablets for oral suspension (brand)

**Oncology – Everolimus Products Preferred Specialty Management Policy non-preferred product(s) is(are) covered as medically necessary when the following non-preferred product exception criteria is(are) met. Any other exception is considered not medically necessary.**

**NON-PREFERRED PRODUCT EXCEPTION CRITERIA**

<b>Non-Preferred Product</b>	<b>Exception Criteria</b>
Afinitor	<p><b>1.</b> Approve for 1 year if the patient meets ALL of the following (A, B, <u>and</u> C):</p> <p><b>A)</b> Patient meets the standard <i>Oncology – Everolimus Products Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient has tried ONE of generic everolimus tablets or Torpenz; AND</p> <p><b>C)</b> Patient cannot continue to use the Preferred medication due to a formulation difference in the inactive ingredient(s) [e.g., difference in dyes, fillers,</p>

	<p>preservatives] which, per the prescriber, would result in a significant allergy or serious adverse reaction.</p> <p><b>2.</b> If the patient has met the standard <i>Oncology – Everolimus Products Prior Authorization Policy</i> criteria (1A), but has <u>not</u> met exception criteria (1B) and/or (1C) above for brand Afinitor: approve generic everolimus tablets or Torpenz.</p>
Afinitor Disperz	<p><b>1.</b> Approve for 1 year if the patient meets ALL of the following (A, B, <u>and</u> C):</p> <p><b>A)</b> Patient meets the standard <i>Oncology – Everolimus Products Prior Authorization Policy</i> criteria; AND</p> <p><b>B)</b> Patient has tried generic everolimus tablets for oral suspension; AND</p> <p><b>C)</b> Patient cannot continue to use the Preferred medication due to a formulation difference in the inactive ingredient(s) [e.g., difference in dyes, fillers, preservatives] which, per the prescriber, would result in a significant allergy or serious adverse reaction.</p> <p><b>2.</b> If the patient has met the standard <i>Oncology –Everolimus Products Prior Authorization Policy</i> criteria (1A), but has <u>not</u> met exception criteria (1B) and/or (1C) above for brand Afinitor Disperz: approve generic everolimus tablets for oral suspension.</p>

## REFERENCES

1. Afinitor® tablets, Afinitor Disperz® tablets for oral suspension [prescribing information]. East Hanover, NJ: Novartis; February 2022.
2. Torpenz™ tablets [prescribing information]. Maple Grove, MN: Upsher-Smith; June 2024.

## HISTORY

Type of Revision	Summary of Changes	Review Date
Annual Revision	No criteria changes.	10/18/2023
Annual Revision	No criteria changes.	06/26/2024
Selected Revision	<b>Afinitor (Brand) Preferred Specialty Management Program:</b> Added Torpenz as one of the Preferred Products. Torpenz is also added to the Afinitor Exception Criteria.	09/25/2024

"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc., Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. © 2024 The Cigna Group.